title: Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation.
abstract: A 17-year-old girl developed refractory rhabdomyosarcoma. An allogeneic peripheral-blood stem-cell transplant was performed after a myeloablative regimen. Although rapid disease progression had resolved transiently, after the start of high-dose chemotherapy, re-progression was apparently observed from day 14. However, delayed tumor regression occurred on day 30, shortly after the reduction of immunosuppressants. She achieved a partial remission. The second tumor regression provides suggestive clinical evidence that graft-versus-tumor effect may occur against rhabdomyosarcoma. Although further investigation is required, allogeneic stem-cell transplantation could provide a new therapeutic option for refractory rhabdomyosarcoma.
authors.affiliation: Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan. amisawa@koto.kpu-m.ac.jp
authors.forename: Akiko
authors.initials: A
authors.lastname: Misawa
authors.forename: Hajime
authors.initials: H
authors.lastname: Hosoi
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Tomoko
authors.initials: T
authors.lastname: Iehara
authors.forename: Tadashi
authors.initials: T
authors.lastname: Sawada
authors.forename: Tohru
authors.initials: T
authors.lastname: Sugimoto
mesh_terms: D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D020350:Graft vs Tumor Effect; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local; D015376:Nimustine / Q000627:therapeutic use; D036102:Peripheral Blood Stem Cell Transplantation; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D019172:Transplantation Conditioning; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D015376:Nimustine; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin; D002945:Cisplatin; D007069:Ifosfamide